DM
KROS icon

Deerfield Management’s Keros Therapeutics KROS Stock Holding History

Deerfield Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-300,000
Closed -$11.3M – 109
2020
Q2 		$11.3M Buy
+300,000
New +$9.24M 0.33% 74

Other funds holding KROS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Deerfield Management's KROS Position: Q3 2020 in Review

Deerfield Management sold out of Keros Therapeutics (KROS) in Q3 2020, closing a stake of 300,000 shares — an estimated $11.3M sold.

Deerfield Management first reported a position in KROS in Q2 2020 and held it in 1 quarter. The position peaked at $11.3M in Q2 2020. 49 funds tracked by Wall St. Rank hold KROS as of Q3 2020.

  • Deerfield Management reported no remaining Keros Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Deerfield Management sold 300,000 Keros Therapeutics shares in Q3 2020, an estimated $11.3M.
  • Deerfield Management first reported a position in Keros Therapeutics in Q2 2020 and held it in 1 quarter.
  • Deerfield Management's Keros Therapeutics position peaked at $11.3M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2020.

Based on Deerfield Management's 13F filing for Q3 2020, filed 16 Nov 2020.